167 related articles for article (PubMed ID: 22415727)
1. Anti-TGF-β antibody combined with dendritic cells produce antitumor effects in osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsuchiya H; Tsumura H
Clin Orthop Relat Res; 2012 Aug; 470(8):2288-94. PubMed ID: 22415727
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
3. Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma.
Kawano M; Nishida H; Nakamoto Y; Tsumura H; Tsuchiya H
Clin Orthop Relat Res; 2010 May; 468(5):1373-83. PubMed ID: 20232181
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma.
Kawano M; Tanaka K; Itonaga I; Iwasaki T; Miyazaki M; Ikeda S; Tsumura H
Oncol Rep; 2015 Oct; 34(4):1995-2001. PubMed ID: 26239052
[TBL] [Abstract][Full Text] [Related]
5. Specific antitumor effects of tumor vaccine produced by autologous dendritic cells transfected with allogeneic osteosarcoma total RNA through electroporation in rats.
Yu Z; Sun H; Zhang T; Yang T; Long H; Ma B
Cancer Biol Ther; 2009 May; 8(10):973-80. PubMed ID: 19287216
[TBL] [Abstract][Full Text] [Related]
6. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.
Terabe M; Ambrosino E; Takaku S; O'Konek JJ; Venzon D; Lonning S; McPherson JM; Berzofsky JA
Clin Cancer Res; 2009 Nov; 15(21):6560-9. PubMed ID: 19861451
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness evaluation of dendritic cell immunotherapy for osteosarcoma on survival rate and in vitro immune response.
Fang X; Jiang C; Xia Q
Genet Mol Res; 2015 Oct; 14(4):11763-70. PubMed ID: 26436501
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.
Kobie JJ; Wu RS; Kurt RA; Lou S; Adelman MK; Whitesell LJ; Ramanathapuram LV; Arteaga CL; Akporiaye ET
Cancer Res; 2003 Apr; 63(8):1860-4. PubMed ID: 12702574
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic and extrinsic manipulation of B7/CTLA-4 interaction for induction of anti-tumor immunity against osteosarcoma cells.
Nagamori M; Kawaguchi S; Murakami M; Wada T; Nagoya S; Yamashita T; Inobe M; Uede T
Anticancer Res; 2002; 22(6A):3223-7. PubMed ID: 12530068
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
11. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.
Soares KC; Rucki AA; Kim V; Foley K; Solt S; Wolfgang CL; Jaffee EM; Zheng L
Oncotarget; 2015 Dec; 6(40):43005-15. PubMed ID: 26515728
[TBL] [Abstract][Full Text] [Related]
12. Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy.
Llopiz D; Dotor J; Casares N; Bezunartea J; Díaz-Valdés N; Ruiz M; Aranda F; Berraondo P; Prieto J; Lasarte JJ; Borrás-Cuesta F; Sarobe P
Int J Cancer; 2009 Dec; 125(11):2614-23. PubMed ID: 19530254
[TBL] [Abstract][Full Text] [Related]
13. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
[TBL] [Abstract][Full Text] [Related]
14. [Inducing specific antitumor effects on osteosarcoma by fused vaccine of rat dendritic cells].
Yu Z; Fan QY; Ma BA; Hao XB; Long H
Ai Zheng; 2005 Mar; 24(3):285-91. PubMed ID: 15757528
[TBL] [Abstract][Full Text] [Related]
15. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
[TBL] [Abstract][Full Text] [Related]
16. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
18. A mathematical model of the enhancement of tumor vaccine efficacy by immunotherapy.
Wilson S; Levy D
Bull Math Biol; 2012 Jul; 74(7):1485-500. PubMed ID: 22438084
[TBL] [Abstract][Full Text] [Related]
19. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
[TBL] [Abstract][Full Text] [Related]
20. Immune approaches to treating osteosarcoma.
Marina N; Gorlick R
Cancer Biol Ther; 2009 May; 8(10):981-3. PubMed ID: 19395866
[No Abstract] [Full Text] [Related]
[Next] [New Search]
